Actavis plunks down $460M for U.K. generics specialist Auden Mckenzie

On an acquisition trail, U.S.-based Actavis ($ACT) has snapped up Auden Mckenzie, a U.K. generics maker, for £306 million in cash plus royalties. The deal, together with its $66 billion Allergan ($AGN) acquisition, will boost Actavis to the No. 1 slot in the U.K. pharma business. Auden Mckenzie will also add to Actavis earnings immediately, the company said. Release

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.